Sildenafil Citrate Tablet, Film Coated
Product Images NDC 71335-3111

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 71335-3111). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (Logo1)

Image Description (Logo1)
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure diagram of sildenafil, the active ingredient in the product Sildenafil Citrate by Bryant Ranch Prepack, showing molecular bonds and functional groups.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line chart depicting systolic blood pressure changes (mmHg) over time (hours) post dose, comparing sildenafil 100 mg and placebo treatments. The x-axis shows time points from pre-dose to 24 hours, and the y-axis shows systolic blood pressure changes ranging from -25 to 15 mmHg. The chart includes two trend lines marked with circles for sildenafil and diamonds for placebo.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the change in systolic blood pressure (SBP) in mmHg over time postdose (hours) for two groups: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg. The time axis ranges from 0 to 8 hours, and the SBP change ranges from -40 to 20 mmHg. Two lines represent SBP changes, with the Sildenafil group generally showing a greater decrease in SBP.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph depicting change in systolic blood pressure (SBP) in mmHg over time postdose (0 to 8 hours). It compares two groups: Doxazosin with placebo (gray line) and Doxazosin with Sildenafil 50 mg (black line), showing SBP changes with time after dosing.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph illustrating the blood pressure change (mmHg) over time (hours) after dosing with either Doxazosin plus Sildenafil 100 mg or Doxazosin plus Placebo. The x-axis represents time after dosing from 0 to 8 hours, and the y-axis shows blood pressure in mmHg, ranging from -50 to 40. Two lines depict the blood pressure trend for each treatment group across the time points.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A pharmacokinetic curve showing plasma concentrations of sildenafil over time post dose. The x-axis represents time in hours post dose, and the y-axis shows plasma concentrations in ng/ml. Data points for the commercial tablet formulation demonstrate peak concentration early after dosing, followed by a gradual decline over 24 hours.*
FDA Label Image

Figure-6-1 (Figure 6 1)

Figure-6-1 (Figure 6 1)
A bar chart depicting the percentage of patients at endpoint versus baseline scores for a clinical parameter, with baseline scores on the x-axis (ranging from 0 to 5) and percentage of patients on the y-axis (0% to 80%). Different shades represent categories labeled 0 through 5.*
FDA Label Image

Figure-6-2 (Figure 6 2)

Figure-6-2 (Figure 6 2)
A bar chart showing the percentage distribution of patients at endpoint across different baseline scores from 0 to 5. The chart uses different shaded bars to represent categories labeled 0 through 5, with the y-axis representing the percentage of patients and the x-axis showing the baseline score values.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A bar graph showing the percentage of patients reporting improvement across four groups: placebo (24% of 463 patients), sildenafil citrate 25 mg (63% of 214 patients), sildenafil citrate 50 mg (74% of 391 patients), and sildenafil citrate 100 mg (82% of 380 patients). The y-axis represents the percentage of patients reporting improvement, ranging from 0 to 100%.*
FDA Label Image

Label (Lbl713353111)

Label (Lbl713353111)
Label for Sildenafil Tablets, USP 50 mg film-coated tablets, repackaged by Bryant Ranch Prepack, Inc. and manufactured by Torrent Pharmaceuticals Ltd. The label includes storage instructions, a quantity of 30 tablets, a QR code for the package insert, and the product NDC 71335-3111-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.